球囊肺动脉成形术与利奥西呱治疗不可手术慢性血栓栓塞性肺动脉高压的随机对照试验
MR BPA 试验在 61 例不可手术 CTEPH 患者中比较球囊肺动脉成形术(BPA)与利奥西呱的疗效与安全性。BPA 组咯血/肺出血更常见(44% vs 4%),BPA 相关并发症发生于 26% 的患者。
要点
- BPA 组咯血或肺出血发生率 44%,利奥西呱组 4%。
- BPA 相关并发症见于 26% 的患者,需在有经验的中心开展。
核心结论
- 在不可手术 CTEPH 患者中,12 个月时 BPA 较利奥西呱更显著降低平均肺动脉压。
- BPA 伴有操作相关并发症,支持其作为有经验术者中心的合理选择。
研究设计与样本
- 开放标签、随机对照试验,在日本 4 个高容量 CTEPH 中心开展。
- 纳入 20-80 岁不可手术 CTEPH 患者,平均肺动脉压 ≥25 至 <60 mmHg,肺动脉楔压 ≤15 mmHg,WHO 功能分级 II 或 III。
- 61 例患者按 1:1 随机分配至 BPA 组(n=32)或利奥西呱组(n=29)。
- 主要终点为基线至 12 个月平均肺动脉压变化,在完整分析集中评估。
主要发现
- 利奥西呱组发生 1 例临床恶化,BPA 组无临床恶化。
关键数值与推荐
- BPA 组目标在首次操作后 4 个月内完成 BPA,重复至平均肺动脉压降至 <25 mmHg。
- 最常见不良事件为咯血/肺出血,BPA 组 14 例(44%),利奥西呱组 1 例(4%)。
- 31 例患者共 147 次 BPA 操作中,17 次(12%)发生 BPA 相关并发症,涉及 8 例患者(26%)。
临床怎么用
- 对于不可手术 CTEPH,BPA 可作为降低平均肺动脉压的治疗选择,但需在有经验的 BPA 操作中心进行。
- 实施 BPA 时应关注操作相关并发症,尤其是咯血或肺出血。
局限性
- 开放标签设计。
- 样本量较小(共 61 例)。
- 仅在日本 4 个高容量中心开展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment options for patients with chronic thromboembolic pulmonary hypertension ineligible for pulmonary endarterectomy (inoperable CTEPH) include balloon pulmonary angioplasty (BPA) and riociguat. However, these two treatment options have not been compared prospectively. We aimed to compare the safety and efficacy of BPA and riociguat in patients with inoperable CTEPH. METHODS: This open-label, randomised controlled trial was conducted at four high-volume CTEPH centres in Japan. Patients aged 20-80 years with inoperable CTEPH (mean pulmonary arterial pressure ≥25 to <60 mm Hg and pulmonary artery wedge pressure ≤15 mm Hg) and WHO functional class II or III were randomly assigned (1:1) to BPA or riociguat via a computer program located at the registration centre using a minimisation method with biased-coin assignment. In the BPA group, the aim was for BPA to be completed within 4 months of the initial date of the first procedure. BPA was repeated until mean pulmonary arterial pressure decreased to less than 25 mm Hg. The frequency of BPA procedures depended on the difficulty and number of the lesions. In the riociguat group, 1·0 mg riociguat was administered orally thrice daily. When the systolic blood pressure was maintained at 95 mm Hg or higher, the dose was increased by 0·5 mg every 2 weeks up to a maximum of 2·5 mg thrice daily; dose adjustment was completed within 4 months of the date of the first dose. The primary endpoint was change in mean pulmonary arterial pressure from baseline to 12 months, measured in the full analysis set (patients who were enrolled and randomly assigned to one of the study treatments, and had at least one assessment after randomisation). BPA-related complications and indices related to clinical worsening were recorded throughout the study period. Adverse events were recorded throughout the study period and evaluated in the safety analysis set (patients who were enrolled and randomely assigned to one of the study treatments, and had received part of or all the study treatments). This trial is registered in the Japan Registry of Clinical Trials (jRCT; jRCTs031180239) and is completed. FINDINGS: Between Jan 8, 2016, and Oct 31, 2019, 61 patients with inoperable CTEPH were enrolled and randomly assigned to BPA (n=32) or riociguat (n=29). Patients in the BPA group underwent an average of 4·7 (SD 1·6) BPA procedures. In the riociguat group, the mean maintenance dose was 7·0 (SD 1·0) mg/day at 12 months. At 12 months, mean pulmonary arterial pressure had improved by -16·3 (SE 1·6) mm Hg in the BPA group and -7·0 (1·5) mm Hg in the riociguat group (group difference -9·3 mm Hg [95% CI -12·7 to -5·9]; p<0·0001). A case of clinical worsening of pulmonary hypertension occurred in the riociguat group, whereas none occurred in the BPA group. The most common adverse event was haemosputum, haemoptysis, or pulmonary haemorrhage, affecting 14 patients (44%) in the BPA group and one (4%) in the riociguat group. In 147 BPA procedures done in 31 patients, BPA-related complications were observed in 17 procedures (12%) in eight patients (26%). INTERPRETATION: Compared with riociguat, BPA was associated with a greater improvement in mean pulmonary arterial pressure in patients with inoperable CTEPH at 12 months, although procedure-related complications were reported. These findings support BPA as a reasonable option for inoperable CTEPH in centres with experienced BPA operators, with attention to procedure-related complications. FUNDING: Bayer Yakuhin. TRANSLATION: For the Japanese translation of the abstract see Supplementary Materials section.
引用
- Kawakami T, Matsubara H, Shinke T, et al. Balloon pulmonary angioplasty versus riociguat in inoperable chronic thromboembolic pulmonary hypertension (MR BPA): an open-label, randomised controlled trial. Lancet Respir Med. 2022. PMID: 35926544. doi:10.1016/S2213-2600(22)00171-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。